Tag Archives: Cory Kasimov

ACADIA Pharmaceuticals (ACAD) Received its Third Buy in a Row

After Cowen & Co. and Needham gave ACADIA Pharmaceuticals (NASDAQ: ACAD) a Buy rating last month, the company received another Buy, this time from J.P. Morgan. Analyst Cory Kasimov maintained a Buy rating on ACADIA Pharmaceuticals yesterday. The company’s shares

ACADIA Pharmaceuticals (ACAD) Gets a Buy Rating from J.P. Morgan

J.P. Morgan analyst Cory Kasimov maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report) on November 25. The company’s shares closed last Monday at $47.17, close to its 52-week high of $48.27. According to TipRanks.com, Kasimov is a

J.P. Morgan Sticks to Its Hold Rating for Allogene Therapeutics (ALLO)

J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Allogene Therapeutics (ALLO – Research Report) yesterday and set a price target of $29.00. The company’s shares closed last Monday at $27.66. According to TipRanks.com, Kasimov is a 4-star analyst

J.P. Morgan Sticks to Their Hold Rating for Regeneron (REGN)

J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Regeneron (REGN – Research Report) yesterday and set a price target of $375.00. The company’s shares closed last Monday at $332.60. According to TipRanks.com, Kasimov is a 4-star analyst with

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE) and Genomic Health (NASDAQ: GHDX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ultragenyx Pharmaceutical (RARE – Research Report) and Genomic Health (GHDX – Research Report). Ultragenyx Pharmaceutical (RARE) J.P. Morgan analyst Cory Kasimov maintained a Buy rating

J.P. Morgan Maintains Their Hold Rating on NovoCure Ltd (NVCR)

In a report issued on October 31, Cory Kasimov from J.P. Morgan maintained a Hold rating on NovoCure Ltd (NVCR – Research Report), with a price target of $79.00. The company’s shares closed last Monday at $75.51. According to TipRanks.com,